These findings provided evidence supporting divergent prognoses for various subtypes and suggested the involvement of various signaling pathways, such as the PI3K/AKT/mTOR axis, in resistance to anoikis of HCC. The gene discussed is MTOR; the disease is hepatocellular carcinoma.